Abeona Therapeutics Leaders to Present at Global Healthcare Conference
Abeona Therapeutics Inc. (Nasdaq: ABEO) has exciting news to share as it announces participation in the esteemed Jefferies Global Healthcare Conference. On an upcoming Wednesday, the spotlight will be on key members of the Abeona team, including the esteemed Dr. Vish Seshadri, CEO, and Dr. Madhav Vasanthavada, CCO. Their presentation, which features a candid fireside chat format, is anticipated to take place at 11:40 a.m. Eastern Time.
Details of the Presentation
The conference serves as a platform for Abeona to discuss the latest advancements in its cell and gene therapy initiatives. A live webcast of this engaging fireside chat can be accessed through the Investors section on Abeona's official website under the 'Events' tab. Additionally, the session will be archived, allowing curious minds to catch up on the insights shared.
Innovative Approaches in Biopharmaceuticals
Abeona Therapeutics is recognized for its pioneering work within the realm of biopharmaceuticals, particularly through its dedication to developing innovative cell and gene therapies aimed at combating serious diseases. One outstanding example of this commitment is Abeona’s ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy designated for treating wounds in both adult and pediatric patients afflicted with recessive dystrophic epidermolysis bullosa (RDEB).
State-of-the-Art Manufacturing Facility
The company boasts a cutting-edge, fully integrated cell and gene therapy cGMP manufacturing facility located in Cleveland, Ohio. This location is crucial, serving as the production site for ZEVASKYN's commercial rollout, and it underscores Abeona’s capabilities and aspirations within the industry.
Advancing Gene Therapy for Ophthalmic Diseases
Abeona's portfolio is not limited to ZEVASKYN, as it also includes a variety of adeno-associated virus (AAV)-based gene therapies targeting ophthalmic diseases marked by high unmet medical needs. A significant aspect of their research focuses on novel, next-generation AAV capsids, which are currently under evaluation to enhance tropism profiles. This advancement aims to ensure better therapeutic outcomes for patients suffering from various debilitating conditions.
Continuing the Commitment to R&D
As the world of biopharma evolves, Abraham Therapeutics remains committed to research and development. Their rigorous pipeline reflects a proactive approach to addressing the pressing healthcare challenges faced today. By continuing to innovate, Abeona is strategically positioned to make a remarkable impact in the treatment landscape, particularly within rare diseases.
Connecting with the Community
The Abeona team encourages stakeholders and interested parties to stay connected through their official website, where updates, events, and detailed information regarding their therapies can be found. This engagement exemplifies their commitment not just to advancing science, but to fostering community understanding and awareness about gene therapies.
Future Prospects and Goals
While the presentation at the Jefferies Global Healthcare Conference serves as a significant milestone for Abeona, it is merely one aspect of their ongoing journey in the biopharmaceutical industry. The company aims to continuously evolve, adapting to the ever-changing landscape of medical innovation, with an unwavering focus on improving patient lives.
Frequently Asked Questions
What is the main focus of Abeona Therapeutics?
Abeona Therapeutics specializes in cell and gene therapies for treating serious diseases, with a focus on innovative treatments such as ZEVASKYN for wound care.
Who will represent Abeona at the Jefferies Global Healthcare Conference?
The presentation will feature Dr. Vish Seshadri, the CEO, and Dr. Madhav Vasanthavada, the Chief Commercial Officer.
How can the public access the fireside chat?
The fireside chat will be available as a live webcast on the Abeona Therapeutics Investors website, with an archive for future viewing.
What is ZEVASKYN?
ZEVASKYN is the first autologous cell-based gene therapy designed for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
What innovations is Abeona looking into for ophthalmic diseases?
Abeona is developing next-generation AAV capsids to improve treatment outcomes in ophthalmic diseases characterized by unmet medical needs.
